Trend is turning up. This has the potential to become a multi-bagger. Citigroup recently upgraded it to a Buy with positive commentary on Mad Money.
The key drivers outlined by the Citi analyst were:
finance.yahoo.com/ne...itive-194127269.html
The key drivers outlined by the Citi analyst were:
- The company's base business is underappreciated by the Street and should drive upside to estimates from its status as the exclusive distributor of Somerset's glycopyrrolate injection, which should see accelerated growth.
- Delays in competitors like hydrocodone APAP that were expected to enter the market in the first half of 2018.
- Execution on new launches of potential durable commercial assets.
- Better-than-expected benefits from the acquisition of the Somerset business.
finance.yahoo.com/ne...itive-194127269.html